TARSUS PHARMACEUTICALS INC's ticker is TARS and the CUSIP is 87650L103. A total of 75 filers reported holding TARSUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 4.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $120,625 | -49.5% | 4,438 | -32.4% | 0.02% | -43.3% |
| Q1 2024 | $238,710 | +207.6% | 6,567 | +71.4% | 0.03% | +100.0% |
| Q4 2023 | $77,598 | +427.4% | 3,832 | +362.8% | 0.02% | +275.0% |
| Q3 2023 | $14,714 | +131.3% | 828 | +135.2% | 0.00% | +100.0% |
| Q2 2023 | $6,361 | +39.8% | 352 | -2.8% | 0.00% | 0.0% |
| Q1 2023 | $4,550 | +14.5% | 362 | +33.6% | 0.00% | 0.0% |
| Q4 2022 | $3,973 | – | 271 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 2,254,797 | $61,285,382 | 6.24% |
| Ikarian Capital, LLC | 800,277 | $21,751,529 | 3.79% |
| TFG Asset Management GP Ltd | 500,000 | $13,590,000 | 3.39% |
| Paradigm Biocapital Advisors LP | 2,435,416 | $66,194,607 | 2.53% |
| Frazier Life Sciences Management, L.P. | 1,587,527 | $43,148,984 | 2.02% |
| Ghost Tree Capital, LLC | 235,000 | $6,387,300 | 2.00% |
| COWEN AND COMPANY, LLC | 2,197,385 | $59,724,924 | 1.64% |
| TCG Crossover Management, LLC | 556,317 | $15,120,696 | 1.58% |
| Sands Capital Ventures, LLC | 170,000 | $4,620,600 | 1.55% |
| BOONE CAPITAL MANAGEMENT LLC | 216,047 | $5,872,157 | 1.53% |